We have established an efficient synthetic methodology for 13-oxyingenol natural derivative (13-oxyingenol 13dodecanoate 20-hexanoate), featuring a ring-closing olefin metathesis reaction for the "direct" construction of a highly strained inside-outside framework and a Mislow-Evans-type [2,3]-sigmatropic rearrangement for the stereoselective introduction of the hydroxy group at C5. We also synthesized artificial analogs of 13-oxyingenol and ingenol by using our synthetic strategy. In vitro activation assays of protein kinase C (PKC) α and δ revealed that the dodecanoyl group at O13 on 13-oxyingenol analogs had a significant role in PKCδ activation. The PKCα-or PKCδ-activating 13-oxyingenol and ingenol analogs induced both distinct morphological changes and increases CD11b expression in HL-60 cells, which would be typical signs of HL-60 cell differentiation to macrophage-like cells, as expected by previous reports. Intriguingly, however, similar differentiation phenotypes were observed with the use of 13-oxyingenol natural derivatives and 13-oxyingenol 13dodecanoate showing a remarkably less potent PKCα or PKCδ activation ability, which PKC inhibitor Gö6983 diminished. This indicated the involvement of other PKC isozymes or related kinase activities. 13-Oxyingenol analogs, which induced HL-60 cell differentiation, also induced HL-60 cell death, similar to the action of a phorbol ester, a strong PKC activator. Scheme 6 Syntheses of precursors for the RCM reaction. Reagents and conditions: (a) 30, NaHMDS, THF, -78 °C; (b) Ac2O, DMAP, py, 50 °C, 83% in two steps for 31; (c) TMSCl, imidazole, DMF, rt, 47% in two steps for 32; (d) Dess-Martin periodinane, CH2Cl2, rt, 81% in two steps for 33. MPM = p-methoxybenzyl, NaHMDS = sodium bis(trimethylsilyl)amide, DMF = N,N-dimethylformamide. Journal Name ARTICLE This journal is Scheme 7 Synthesis of allylic alcohol 26. Reagents and conditions: (a) DIBAL, toluene, -78 °C, 96%; (b) MsCl, Me2N(CH2)3NMe2, toluene, 0 °C; (c) (PhSe)2, NaBH4, THF, EtOH, rt, 96% in two steps; (d) m-CPBA, THF, -78 °C; (e) P(OMe)3, MeOH, 0 °C, 76% in two steps. Ms = methanesulfonyl, m-CPBA = mchloroperbenzoic acid.
Introduction
-oxyingenol 13-dodecanoate 20-hexanoate (13-oxyingenol natural derivative; 13-oxyingenol derivative) (1) was isolated from Euphorbia kansui plants by Uemura et al. (Figure 1 ). 1 The structural features of 1 is a high degree of oxygenation and a highly strained unique bicyclo[4.4.1]undecane skeleton with trans intrabridgehead stereochemistry at the BC rings, which is called an inside-outside framework. Ingenol (3) has the same framework of 1, 2 and ingenol 3-angelate (Picato ® ) (4) was approved by the FDA as a topical treatment for solar keratosis. 3 In 1996, Fujiwara et al. reported the structureactivity relationship study of 1. 4 As a results, a 13-oxyingenol analog, RD4-2227 (2), showed a potent inhibitory effect at picomolar concentrations on HIV-1 (HTLV-III B ) replication in MT-4 cells (EC 50 = 140 pM). This is stronger than the inhibitory effect of 3 (5,200,000 pM) or of anti-HIV drug zidovudine (Retrovir ® ) (4,100 pM) under the same assay conditions. Ingenol analogs are reported to be involved in the modulation of protein kinase C (PKC) enzyme activity. 5 PKCs are a family of serine/threonine kinases and are key mediators of many intracellular signal transduction pathways involved in cell growth, differentiation, carcinogenesis and cell death. 6 PKCs are categorized into three classes: conventional (cPKCs), novel (nPKCs), and atypical (aPKCs). The binding of ligands such as endogenous second messenger diacylglycerol (DAG) and tumor promoter phorbol esters (e.g., phorbol 12-myristate 13acetate; PMA) to the C1 domain in cPKCs and nPKCs, but not in aPKCs, triggered the enhancement of enzymatic activity. The crystal structure of the PKCδ C1 domain with phorbol ester revealed crucial hydrogen bonding interactions between the hydrophilic cleft of the C1 domain and phorbol esters. 7 Some ingenol derivatives, especially those that have an acyl group on the hydroxyl group at C3, were reported to be C1 domain ligands and to activate PKC, which was explained by their structural similarities with phorbol esters. For 13-oxyingenol analogs, RD4-2227 (2) was identified as a potent nontoxic PKC activator (no toxicity was observed in mice up to 0.1 mg kg -1 day -1 by intraperitoneal injection). 4a Non-tumor-promoting PKC activators, such as bryostatin 1, 8 prostratin, 9 and aplysiatoxin analogs, 10 have been attracting attention as potential therapeutic agents for acquired immune deficiency syndrome (AIDS), tumors, and Alzheimer's disease. Thus, the activities of 13-oxyingenol analogs, which have an additional functionalization site at the C13 position in 13-oxyingenol as compared to ingenol analogs, have been of great interest. However, the structure-activity relationships of 13-oxyingenol derivatives are still largely unknown, which hampers further rational molecular design and obscures the merit of 13oxyingenols for use as parent compounds. We anticipated that the development of an efficient synthetic methodology for 1 would enable us to provide a practical synthetic route for research supply of its analogs and to conduct further biological studies in order to uncover the characteristic features of 1.
The unique stereostructures of the ingenol family have made them attractive targets for total synthesis. 11 Four groups have achieved the total synthesis of ingenol (3): Winkler, 12 Tanino-Kuwajima, 13 Wood, 14 and Baran 15 . Also, several groups have reported the synthesis of the ingenol skeleton. 16 Whereas many groups have constructed the highly strained insideoutside framework of 3 by using rearrangement or fragmentation reactions, we developed a "direct" construction method using the ring-closing olefin metathesis (RCM) reaction. 17 We then achieved the formal synthesis of optically active 3 using this methodology as a key step. 18 Wood et al.
accomplished the total synthesis of ingenol by using similar approach in 2004. 14 We also have investigated the synthesis of 13-oxyingenol derivative (1). 19 In 2012, we preliminarily reported the total synthesis of 1. 20 The highlights of this approach are the use of an RCM reaction for the direct construction of an inside-outside framework and a Mislow-Evans-type [2,3]-sigmatropic rearrangement 21 for the stereoselective introduction of a hydroxy group at C5. We describe herein the history of the total synthesis of 13oxyingenol derivative (1). Furthermore, we discuss the synthesis and activities against PKC of the C3-acyloxy 13oxyingenol and ingenol analogs.
Results and disscussion

Construction of the A-ring portion of 13-oxyingenol derivative (1)
The retrosynthetic pathway of 13-oxyingenol derivative (1) is shown in Scheme 1. We planned to construct the B-ring portion by using ring-opening reaction of the epoxy group in 5. To introduce the requisite functional groups at the A-ring portion, we decided to use the introduced hydroxy group at C2. The secondary hydroxy group at the C5 in the B-ring portion would be introduced by using regio-and stereoselective epoxidation of allylic alcohol 6 and the subsequent ringopening reaction of the epoxy group in 5. Allylic alcohol 6 was prepared by regio-and stereoselective dihydroxylation at the most strained ∆ 3,4 olefin in triene 7, which might be obtained from tetracyclic ketone 8. The inside-outside framework of 8 was prepared by using an RCM reaction of diene 9. Diene 9 can be synthesized from spiro-ketone 10.
Scheme 1 Retrosynthetic pathway of 13-oxyingenol derivative (1).
The synthesis of epoxide 5 started from the spiro-ketone 10, which is our previous intermediate (Scheme 2). 19c Thus, the introduction of an allyl group to the C8 position of spiroketone 10 with iodide 11 gave diene 9. Diene 9 was treated with the second-generation Hoveyda-Grubbs (HG-II) catalyst (37) 22 to afford tetracyclic ketone 8, which possessed the inside-outside framework. We attempted the stereoselective introduction of the functional groups at the A-and B-rings from 8. The removal of the MPM group of 8 followed by oxidation of the resulting secondary hydroxy group with Dess-Martin periodinane 23 gave diketone 12. We next tried to Please do not adjust margins Please do not adjust margins synthesize enone 13 from 12. Regioselective deprotonation at the H3 in 12 and silylation of the resultant enolate with TMSCl gave an enol silyl ether as the sole product, which was oxidized by using Ito-Saegusa oxidation 24 to afford 13 (95% yield in two steps). In this deprotonation of 12, deprotonation at the H1 did not proceed, presumably due to the steric hindrance of the methyl group at the C18. Enone 13 was converted into an enol triflate, which was subjected to the Negishi coupling 25 reaction with Me 2 Zn to afford triene 7. Regio-and stereoselective dihydroxylation of 7 with a stoichiometric amount of OsO 4 gave diol 14. The high regio-and stereoselectivity could be explained by the shielding of the ∆ 1,2 olefin by the steric hindrance of the C18 methyl group and by the enhancement of the reactivity by the pyramidal distortion of ∆ 3,4 olefin. We succeeded in synthesizing the A-ring portion of 13-oxyingenol derivative (1) by using the C2 hydroxy group. Next, we attempted to functionalize the B-ring portion of 1. Protection of the secondary hydroxy group of 14 with a benzoyl group gave allylic alcohol 6, which was converted into epoxide 5 as a single isomer. In this epoxidation, stereoselectivity was controlled by the tertiary hydroxy group at the C4 and the cage structure of 6. The stereochemistry of 5 was established by Xray crystallographic analysis of crystalline p-bromobenzoate 15 ( Figure 2 ). Please do not adjust margins
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With a fully substituted tetracyclic compound 5 in hand, we next tried the ring-opening reaction of the epoxy group in 5 (Table 1 ). In entries 1 and 2, the ring-opening reaction of the epoxy group was investigated by using TfOH as a Brønsted acid or Al(O i Pr) 3 as a Lewis acid. 26 However, the desired compound 16 was not obtained. Next, the ring-opening reaction was examined by using TMSOTf and DBU (entry 3). 27 Again, however, the reaction did not give 16, but rather undesired compounds 17 and 18. The production of these undesired compounds can be explained as follows (Scheme 3). First, the carbonyl group at the C9 in 5 was activated by TMSOTf as 20, and allylic cations 21 and 22 were generated by the migration of blue or green bonds, respectively. The methyl proton at the C19 in the resulting cations 21 and 22 were removed by DBU to give compounds 17 and 18, respectively. Because the desired epoxide-opening reaction under acidic conditions did not afford 16, we next investigated the reaction under basic conditions (entries 4 and 5). The ring-opening reaction of 5 with LDA was attempted, but 16 was not obtained (entry 4). This reaction afforded a complex mixture containing byproducts, such as those that seemed to form via the allylic anion at the C19 in 5. In entry 5, the treatment of 5 by an aluminum amide 28 The fragmentation of 24 and the subsequent ring-opening reaction of the cyclopropane ring formed compound 19. The structure of 19 was determined by X-ray crystallographic analysis. 30 Despite these attempts, we could not establish reaction conditions for the ring-opening reaction of the epoxy group in 5. Therefore, we reexamined the strategy of constructing the A-and B-ring portions of 13-oxyingenol derivative (1). 
Construction of the B-ring portion of 13-oxyingenol derivative (1)
The modified retrosynthetic pathway of 13-oxyingenol derivative (1) is shown in Scheme 5. As mentioned above, we established the functionalization of the A-ring portion. In this section, we mainly describe the construction of the B-ring portion of 1. We planned to introduce the ∆ 6,7 olefin and chiral secondary hydroxy group at the C5 in the B-ring portion by using Mislow-Evans-type [2,3]-sigmatropic rearrangement.
21,31
This strategy has the benefit of constructing the ∆ 6,7 olefin and the C5 stereocenter at once. This precursor 27 might be obtained from alcohol 28 by S N 2 reaction with a selenide anion at the C7. Alcohol 28 was synthesized by an aldol reaction between 10 and the unsaturated aldehyde 30 for the introduction of the hydroxy group at the C7 and the ringclosing olefin metathesis reaction of the resultant 29.
Scheme 5 Modified retrosynthetic pathway of 13-oxyingenol derivative (1).
We prepared precursors for the RCM reaction, such as 29, from spiro-ketone 10 (Scheme 6). The aldol reaction between 10 and unsaturated aldehyde 30 32 gave allylic alcohol 29 as a single diastereomer. The stereochemistry of C7 in 29 was determined after the RCM reaction. Aldol 29 was converted into acetate 31, TMS ether 32, and unsaturated ketone 33 as the precursors for the RCM reaction.
Next, the RCM reactions of the precursors were optimized ( Table 2 ). We examined the RCM reactions of precursors 29 and 31-33 with HG-II catalyst (37) . 22 First, the RCM reaction of allylic alcohol 29 was attempted, but the yield was moderate (54%) (entry 1). Because this reaction gave spiro-ketone 10, we supposed that a retro-aldol reaction occurred under this RCM condition. We next investigated the RCM reactions with acetate 31 and the TMS ether 32. However, the yields were still moderate (entry 2: 64%, entry 3: 49%). These results indicated that the RCM reaction was most efficiently effected by using 31. Therefore, we next screened solvents by using 31 as a precursor. In entry 4, we attempted the RCM reaction in boiling benzene, but the yield was low. Halogenated aromatic solvents, such as 1,2-dichlorobenzene (reaction at 120 °C) and trifluorobenzene (reaction at reflux) (entries 5 and 6) did not improve the yields. We also screened an assortment of Ru catalysts. The RCM reaction with highly active Ru catalyst 38 33 afforded tetracyclic ketone 34 in 51% yield (entry 7), whereas the RCM reaction with the less-hindered Ru catalyst (Stewart-Grubbs catalyst) 39 34 did not yield the desired compound 34
(entry 8). These results indicated that the use of acetate 31 cannot improve the yield of the RCM reaction. Next, we tried the RCM reaction with α,β-unsaturated ketone 33 as a precursor, because the steric hindrance around the C7 of the α,β-unsaturated ketone group at C7 is smaller in 33 than in acetate 31 and because the reactivity of the enone is suitable for the RCM reaction. The reaction of α,β-unsaturated ketone 33 with HG-II catalyst (37) in boiling toluene proceeded smoothly to afford the desired tetracyclic ketone 36 in 86% yield (entry 9). On the basis of these results, we established an optimized precursor and reaction conditions for the RCM reaction. With tetracyclic ketone 36, which has an oxygen functional group at the C7, in hand, we examined the construction of the B-ring portion. Reduction of the carbonyl group at the C7 in 36 proceeded from the convex face in a highly stereoselective manner to give allylic alcohol 28 (Scheme 7). Mesylation of the resultant hydroxy group of 28 by the Tanabe method 35 afforded mesylate 40, and the introduction of a phenylselenyl group by the selenide anion prepared from (PhSe) 2 and NaBH 4 gave selenide 41. Oxidation of 41 by m-CPBA gave a selenoxide, which was treated with P(OMe) 3 to afford [2,3]-sigmatropic rearrangement product 26. Thus, we established the construction of the B-ring portion by using [2,3]-sigmatropic rearrangement as a key step.
Protection of the secondary hydroxy group in 26 with a TES group and removal of two MPM groups afforded diol 49 (Scheme 10). The primary alcohol in 49 was protected as a TBS group, and the remaining secondary hydroxy group at the C2 was oxidized by Dess-Martin periodinane to give diketone 50. Diketone 50 was oxidized to enone 51 by using Ito-Saegusa oxidation. In this case, a rearrangement compound, such as compound 45, was not afforded. Enone 51 was converted into an enol triflate, which was transformed into triene 52 by using Negishi coupling. Next, the regio-and stereoselective dihydroxylation of 52 with a stoichiometric amount of OsO 4 was carried out. However, the desired diol 53 was not obtained, but rather the undesired compound 54, which was oxidized at the ∆ 6,7 olefin, was obtained. We thought that steric hindrance of the TES group in 52 interfered with the electrophilic attack of OsO 4 at the ∆ 3,4 olefin. We found it difficult to introduce functional groups at the Aring portion after the construction of the B-ring portion. Thus, we next tried to construct the A-ring portion before constructing the B-ring portion. Removal of two MPM groups in 34 and subsequent hydrolysis of the acetyl group gave a triol, which was converted into acetonide 55 (Scheme 11). Acetonide 55 was transformed into diol 56 by using our established synthetic strategy (Scheme 2). Protection of the diol group in 56 with a cyclic carbonate group and removal of the TBS group gave a diol, which was transformed into alcohol 57 by selective silylation of the primary hydroxy group. We next examined the introduction of a phenylselenyl group at the C7 in 57. The mesylation of 57 afforded mesylate 58, which was treated with (PhSe) 2 and NaBH 4 . However, selenide 59 was not obtained. This suggested that steric hindrance of the cyclic carbonate group in 58 interfered with the nucleophilic attack by a selenide anion. 
Total synthesis of 13-oxyingenol derivative (1)
As described above, we constructed each of the A-and B-ring portions of 13-oxyingenol. However, we were unable to construct both of A-and B-rings in a molecule (Schemes 8 and 10). Therefore, we attempted to construct the A-ring portion at the next stage of the introduction of an aromatic selenyl group at the C7 (Scheme 12). Two MPM groups in selenide 41 were removed by using DDQ to afford diol 60. Selective protection of the primary hydroxy group of 60 with a TBS group and the remaining secondary hydroxy group at the C2 was oxidized by Parikh-Doering oxidation 37 to give diketone 62.
Other oxidation conditions, such as Dess-Martin oxidation and Ley-Griffith oxidation, 38 gave Mislow-Evans-type rearrangement byproducts along with desired 62. Diketone 62 was oxidized into enone 63 by using Ito-Saegusa oxidation. Enone 63 was treated with LHMDS and Tf 2 NPh to form an enol triflate, which was subjected to Negishi coupling to afford triene 64. Regio-and stereoselective dihydroxylation of the ∆ 3,4 olefin in triene 64 with a stoichiometric a mount of OsO 4 gave the desired diol 65. During conversion of selenide 41 into 65, the phenylselenyl group was not affected by oxidizing agents, such as DDQ, SO 3 ·py-DMSO, and OsO 4 . We next examined the introduction of the C5 hydroxy group by using a Mislow-Evans-type rearrangement. The oxidation of the aromatic selenide group in 65 using m-CPBA and subsequent [2, 3] -sigmatropic rearrangement with P(OMe) 3 afforded triol 66. Thus, both the A-and B-ring portions of 13-oxyingenol derivative (1) were successfully constructed. The removal of two TBS groups in 66 afforded 13-oxyingenol (67), and four hydroxy groups at the A-and B-ring portions of 67 were protected as two acetonide groups to afford compound 68.
The introduction of the dodecanoyl ester group at the remaining tertiary hydroxy group at C13 in 68 gave 69, which was hydrolyzed into 13-oxyingenol 13-dodecanoate (70). Finally, selective acylation of the primary hydroxy group in tetraol 70 formed 13-oxyingenol derivative (1). The spectral data ( 1 H NMR and 13 C NMR spectroscopy, HRMS, and optical rotation) of synthetic 1 were in full agreement with those of the natural product, thus completing the total synthesis (1.4% overall yield in 41 steps). 10 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx
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Synthesis of artificial analogs of the 13-oxyingenols and ingenols
To investigate the structure-activity relationship of 13oxyingenol derivative (1), we prepared artificial analogs of 13oxyingenol. Because RD4-2227 (2) and ingenol 3-angelate (4) show potent biological activity, we focused on the C3-acyloxy 13-oxyingenol analogs. We synthesized the C3-acyloxy analogs from our synthetic intermediate 70 (Scheme 13). Selective protection of the 1,3-diol group at C5 and C20 with an acetonide group gave mono acetonide 71. 39 Selective acylation of the O3-hydroxy group and removal of the acetonide group afforded various C3-acyloxy 13-oxyingenol analogs, pivalate 2 (RD4-2227), angelate 76, tetradecanoate 77, and benzoate 78.
On the other hand, to examine the effect of the dodecanoyl ester group at the C13 in 13-oxyingenol analogs, C3-acyloxy ingenol analogs 4 and 84-86 were also prepared from ingenol (3) 40 by using the same strategy for the C3-acyloxy 13oxyingenol analogs.
PKCα and PKCδ activation abilities of 13-oxyingenol natural derivative (1) and its artificial analogs
The enhancement of PKC activity by 13-oxyingenol and ingenol analogs was evaluated in vitro for PKCα (as a representative of cPKCs) and PKCδ (as a representative of nPKCs). First, the effects of the compounds (10 nM for PKCα and 100 nM for PKCδ) on the enzyme activities were examined. As shown in Table 3 , analogs without the acyl group on the O3 position (R 2 = H) did not show significant activation of either PKCα or PKCδ, indicating that the 3-acyloxy group is essential for PKC activation as suggested previously. 4a,15c Other derivatives showed the dose-dependent activation of PKCα and PKCδ ( Figures S2 and S4) . Regardless of the presence or absence of the 13-acyloxy group (R 1 ), a similar activation level of PKCα was observed for ingenol analogs (4, 84-86) and 13-oxyingenol analogs (2, (76) (77) (78) . In contrast, it should be noted that PKCδ activity was clearly susceptible to the 13-acyloxy group. Though compounds 2, 76, and 78 exhibited remarkable activation of PKCδ, the corresponding ingenol analogs (4, 84, and 86) showed much lower activation. The bulkiness of the 3acyl group (R 2 ) also seemed to affect PKCα activation ability, as we observed in our isobenzofuranone ligands before. 41 The branched pivaloyl derivatives (2 and 84) showed stronger activation than the straight chain myristoyl analogs (77 and 85).
These results indicated that 13-oxyingenol analogs with a long acyl chain at the C13 position and a short bulky acyl group at the C3 position have the potential for broad activation ability toward both cPKCs and nPKCs. On the other hand, the activation abilities of compound 77 having two long straight acyl chains similar to DAGs were low, and indeed were lower than those of compound 85, which lacks a long acyl chain at C13.
HL-60 cell differentiation and cell death
We further examined the biological effects of 13-oxyingenol analogs at the cellular level. It has been reported that ingenol 3-angelate (4) induced the differentiation and apoptosis of HL-60 cells, and that PKCδ would play a critical role in these effects. 42 Since CD11b was reported as an early marker of HL-60 cell differentiation, the expression levels of CD11b of HL60 cells treated with PMA and the ingenol and 13-oxyingenol analogs (1 μM, 24 hr) were measured by flow cytometry. The relative expression levels (%) compared to PMA are shown in Table 3 . CD11b expression was greatly induced by all of the compounds except compounds 67 and 3 (see also Figure S6 ). Furthermore, morphological changes in HL-60 cells, cell aggregation, cell attachment and pseudopodia formation, induced by these ingenol and 13-oxyingenol analogs were confirmed by microscopic observations (Figure 3 and Figure  S5 ). In addition, the induction of apoptosis by the treatment of these compounds (1 μM, 48 hr) was also quantified by measuring the sub-G1 population by flow cytometry. Similar to ingenol 3-angelate (4), these compounds induced apoptosis ( Table 3 and S7). Compounds 67 and 3, each lacking the ability to active PKCα and δ, did not induce morphological changes, expression of CD11b, or the death of HL-60 cells. These results suggested that PKCδ activation might be involved in the mode of action of HL-60 differentiations and apoptosis induced by ingenol and 13-oxyingenol analogs, as reported previously. 42 However, 13oxyingenol derivatives (1) and 13-oxyingenol 13-dodecanoate (70), each showing less potent PKCδ activation in vitro than PMA, significantly induced HL-60 cell differentiation and apoptosis (Table 3 , Figures S3, S5, and S6 ), suggesting that these compounds induce activations of other PKC isozymes, although the possibility that migration of acyl groups in 1 and 70 altered these compounds to be stronger PKC activators could not be excluded. 39b Therefore, the effects of broadspectrum PKC inhibitor Gö6983 on CD11b expression were examined. Interestingly, Gö6983 suppressed the upregulations of CD11b induced by 1 and 70 as well as other compounds ( Figure S8 ). These results indicated that the activation of other PKC isozyme (or other kinases that Gö6983 inhibits) might contribute to HL-60 cells differentiation induced by these 13-oxyingenols. Please do not adjust margins Please do not adjust margins 
Conclusions
We have achieved the total synthesis of 13-oxyingenol derivative (1), featuring the RCM reaction for the construction of an inside-outside framework and Mislow-Evans-type [2,3]sigmatropic rearrangement for the stereoselective introduction of a hydroxy group at C5. The efficient functionalization of the A-and B-ring portions was established by using C2 and C7 hydroxy groups. Furthermore, we have investigated the structure-activity relationships (SAR) of 13oxyingenol derivative (1) and ingenol (3) . SAR studies of synthetic 13-oxyingenol analogs for PKCα and PKCδ activation reinforced the importance of esterification at the C3 hydroxyl group for PKC activation, and 2 and 76 proved to be the most powerful PKCδ activators. We also found that there are 13oxyingenol analogs having a long hydrophobic alkyl chain that induced HL-60 cell differentiation and cell death, though they were poorer PKCα and PKCδ activators than others or PMA. This showed the potential of 13-oxyingenol as a new scaffold for the development of therapeutic agents against acute myeloid leukemia. Various artificial analogs of 13-oxyingenol prepared by our synthetic strategy of 1 enabled us to obtain these new findings.
